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Trichomonas vaginalis may be emerging as one of the most important cofac-
tors in amplifying HIV transmission, particularly in African-American communi-
ties of the United States. In a person co-infected with HIV, the pathology
induced by  T. vaginalis infection can increase HIV shedding. Trichomonas
infection may also act to expand the portal of entry for HIV in an HIV-negative
person. Studies from Africa have suggested that  T. vaginalis infection may
increase the rate of HIV transmission by approximately twofold. Available data
indicate that T. vaginalis is highly prevalent among African-Americans in major
urban centers of the United States and is often the most common sexually
transmitted infection in black women. Even if T. vaginalis increases the risk of
HIV transmission by a small amount, this could translate into an important
amplifying effect since Trichomonas is so common. Substantial HIV transmis-
sion may be attributable to T. vaginalis in African-American communities of the
United States. 
Trichomonas vaginalis is a protozoan parasite transmit-
ted principally through vaginal intercourse. Infection with
the organism, while frequently asymptomatic, can cause
vaginitis in women and urethritis in men. Despite a relative
paucity of studies on the prevalence and incidence of tri-
chomoniasis, recent publications suggest that T. vaginalis is
one of the most common sexually transmitted infections
(STIs) in the United States, with an estimated 5 million new
cases occurring annually (1). Although the organism appears
to be highly prevalent and has a widespread geographic dis-
tribution, Trichomonas has not been the focus of intensive
study nor of active control programs. This neglect is likely a
function of the relatively mild nature of the disease (2), the
lack of effect on fertility, and the historic absence of associa-
tion with adverse birth outcomes (although recent data sug-
gest a possible causal role in low birth weight and
prematurity [3]). However, Trichomonas may play a critical
and underrecognized role in amplifying HIV transmission
(4). We present the rationale to support the hypothesis that
T. vaginalis may be an important cofactor in promoting the
spread of HIV and, in some circumstances, may have a major
impact on the epidemic dynamics of HIV in African-Ameri-
can communities.
Biologic Rationale
Expanding the Portals of Entry and Exit
T. vaginalis infection typically elicits an aggressive local
cellular immune response with inflammation of the vaginal
epithelium and exocervix in women and the urethra of men
(5). This inflammatory response induces a large infiltration
of leukocytes, including HIV target cells such as CD4+ bear-
ing lymphocytes and macrophages to which HIV can bind
and gain access (6,7). In addition, T. vaginalis can frequently
cause punctate mucosal hemorrhages (8). In an HIV-nega-
tive person, both the leukocyte infiltration and genital
lesions induced by  Trichomonas may enlarge the portal of
entry for HIV by increasing the number of target cells for the
virus and allowing direct viral access to the bloodstream
through open lesions. Similarly, in an HIV-infected person
the hemorrhages and inflammation can increase the level of
virus-laden body fluids, the numbers of HIV-infected lym-
phocytes and macrophages present in the genital contact
area, or both. The resulting increase of both free virus and
virus-infected leukocytes can expand the portal of exit,
thereby heightening the probability of HIV exposure and
transmission to an uninfected partner. Increased cervical
shedding of HIV has been shown to be associated with cervi-
cal inflammation (9), and substantially increased urethral
viral loads have been documented in men with Trichomonas
infection (10). In addition, T. vaginalis has the capacity to
degrade secretory leukocyte protease inhibitor, a product
known to block HIV cell attachment; this phenomenon may
also promote HIV transmission (11). Moreover, since most
patients with Trichomonas infection are asymptomatic or
mildly symptomatic (12), they are likely to continue to
remain sexually active in spite of infection. Studies suggest
that approximately 50%-70% of persons with  T. vaginalis
have subclinical infection (12). 
Empiric Evidence Implicating
Trichomonas in HIV Transmission
Data from studies conducted in Africa have shown an
association between  Trichomonas and HIV infection, sug-
gesting a two- to threefold increase in HIV transmission
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(4,13,14). A cross-sectional study conducted among 1,209
female sex workers in the Ivory Coast found an association
between HIV and  Trichomonas infection in bivariate analy-
sis (crude odds ratio 1.8, 95% confidence intervals 1.3, 2.7).
In another cross-sectional study performed in Tanzania
among 359 women admitted to a hospital for gynecologic
conditions, Trichomonas was more common in women with
HIV infection in multivariate analysis (odds ratio 2.96, no
confidence intervals provided, p<0.001). While such cross-
sectional studies are limited by the issue of temporal ambi-
guity, i.e., lack of information on whether Trichomonas infec-
tion preceded HIV, these preliminary findings were
subsequently reinforced in a single prospective study from
Zaire (4). This study, in which 431 HIV-negative female
prostitutes were evaluated over time, found that prior Tri-
chomonas infection was associated with a twofold increased
rate of HIV seroconversion in muiltivariate analysis.
Data on the Prevalence of
T. vaginalis among U.S. Women
Information on the occurrence of  T. vaginalis infection
in the United States is meager. Trichomoniasis is not a
reportable condition in most health jurisdictions, and preva-
lence surveys for STIs often do not include attempts to
recover  Trichomonas. In addition, the relatively few pub-
lished studies with information on the prevalence of T. vagi-
nalis infection have generally been conducted among highly
selected populations, typically included only women, or were
limited by small numbers of participants. Frequently these
studies were not conducted with the primary purpose of
assessing the prevalence of Trichomonas. Moreover, many of
these studies have often used diagnostic techniques with rel-
atively low sensitivity such as wet mount, stained prepara-
tions, or Papanicolaou (PAP) smear. Wet mount, the most
commonly used method, has an estimated sensitivity of 58%
when compared with culture (15); the sensitivity of PAP
smear is approximately 57%. The accuracy of these tech-
niques is dependent on the experience of the microscopist,
and sensitivities may vary widely (15). The sensitivity of cul-
ture when compared with polymerase chain reaction (PCR)
has been estimated to be 70% (16). Such highly sensitive
PCR and related techniques are not routinely used nor
readily available for Trichomonas as for other STIs (17). As a
result of suboptimal laboratory methods, studies of T. vagi-
nalis have often substantially underestimated the preva-
lence of infection. In spite of this, levels of infection have
typically been high, with reported overall prevalences rang-
ing from 3% to 58% and an unweighted average across stud-
ies of 21% (18-37).
Table 1 lists published reports on the occurrence of
T. vaginalis infection among women conducted among U.S.
populations from 1964 through 1999. Although not
Table 1. Studies of the prevalence of  Trichomonas vaginalis infection in women, United States, 1964–1997
Yeara Location (ref) N Population
Trichomonas
prevalence (%) Diagnostic method(s)
1996-97 New York (18) 213 Incarcerated 47 culture
1995-97 St. Louis (19) 143 HIV clinic 11 wet mount
1993-95 4 cities (20) 1,285 HIV infected and high risk 11 wet mount
1994 New York (23)  1,404 Inner city 20 not provided
1992 Baltimore (24) 279 STD clinic 26 culture
1990-94 New York (37) 677 HIV and community clinics 22 culture
1901-93 Southeastern city 
(21)
650 Adolescent health clinics 3 culture
1986 5 cities (27) 13,816 Antepartum women 13 culture
1990-91 New York (22) 372 Inner city 27 culture
1989-90 New York (25) 1,401 OB/GYN clinics 20 culture
1989 Baltimore (26) 3,005 Cancer screening 25 wet mount
1987-88 Denver (36) 5,681b STD clinic 11 wet mount
1984-86 Birmingham (28) 818 STD clinic 21 wet mount
1985 San Francisco (29) 171 Adolescent clinic 11 wet mount/PAPc
1982 Baltimore (30) 115 Pregnant adolescents 34 culture
1981 Seattle (31) 80 Juvenile detention 48 wet mount 
1980 Providence (32) 500 Student health center 3 culture
1979-80 Storrs (33) 383 GYN clinic 19 wet mount/PAP
1971 Oregon (34) 338 State school/adolescents 35 Gram stain
1964 Philadelphia (35) 27,392 Cancer screening 16 PAP
aYear of study (or publication).
b Number of visits.
cPapanicolaou smear; STD = sexually transmitted disease; OB/GYN = obstetrics/gynecology.Synopsis
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necessarily complete, a comprehensive search through MED-
LINE and review of articles yielded only 20 reports during
this 35-year period. Evaluated populations have included
such groups as sexually transmitted disease (STD) clinic
patients, inner-city populations, pregnant women, university
students, adolescents, incarcerated populations, and women
with HIV infection.
Data on the Incidence of
T. vaginalis in the United States
Even fewer studies have assessed the incidence of tri-
chomoniasis in the United States. In a study conducted from
1992 to 1995 among a cohort of 212 women with HIV in Los
Angeles County,  Trichomonas infection was the most fre-
quently identified sexually transmitted disease and was
found in 37 (17.4%) women, representing a crude incidence
rate of 14.1 per 100 person-years’ experience (38). The crude
rate was highest in black women (69.0 per 100 person-years).
A recent prospective study conducted from 1990 to 1998 in
New Orleans, which followed women co-infected with HIV
and T. vaginalis, documented high rates (16.1 per 100 per-
son-years) of  Trichomonas re-infection (39). Among a pre-
dominantly black group of HIV-infected and high-risk
women followed in New York City from 1990 to 1994, T. vag-
inalis was the most frequent incident STI (37).
Prevalence of T. vaginalis among
Men in the United States
Very few published studies have assessed the preva-
lence of  T. vaginalis among men and, as is the case for
women, these studies typically have included relatively
small samples from selected populations. Often data on race-
specific prevalences are not provided. Among men attending
an STD clinic in Seattle-King County from 1987 to 1990, 6%
of 300 randomly selected men were infected with Trichomo-
nas by culture technique; 22% of 147 contacts to women with
T. vaginalis were also positive (40). In a study published in
1995 conducted in Richmond, California, 12% of 204 male
patients from an STD clinic were culture positive for T. vagi-
nalis  (41). Among 454 consecutive men attending an STD
clinic in Denver in 1998, 2.8% were found to be infected by a
culture method (42). In a small-scale study published in
1991 among 16- to 22-year-old black men enrolled in an
inner-city residential youth job-training program, Trichomo-
nas was recovered from 55% of 85 participants and was the
most common STI identified (43). Data on race-specific prev-
alences of Trichomonas infection among U.S. males are not
available. We are unaware of any published reports that
have assessed the prevalence of  T. vaginalis in males and
females. While the separate studies we have cited suggest
that Trichomonas may be more common in women in the
United States, the data are so limited and potentially biased
that any such conclusions must be made cautiously.
Race and Trichomonas
Table 2 presents data, where available, on the preva-
lence of Trichomonas among women, by race, in the United
States. In each study that has presented information on
race/ethnicity, the prevalence of Trichomonas has been high-
est in African-Americans (23%-51%), ranging from approxi-
mately 1.5 to nearly 4 times greater than other racial/ethnic
groups. In several studies in which very high prevalences of
infection were observed, the population consisted exclusively
or predominantly of African-Americans. This racial finding,
consistent across studies, is unlikely to be artifactual.
Several factors may explain the apparent elevated rate
of trichomoniasis in black women. This phenomenon may
indicate a high prevalence of Trichomonas infection among
the sex partners of these women. Although a study in Wash-
ington, D.C., observed a high prevalence of  T. vaginalis
(55%) among young, inner-city, black men (43), data on race-
specific rates of Trichomonas infection in men are lacking.
The association with black race may also reflect decreased
use of barrier protection in this population. Studies indicate
that African-American males are less likely to use condoms
than men of other racial groups because of a higher fre-
quency of condom breakage and slippage (44) and a reported
decrease in sexual fulfillment (45). Alternatively, it is possi-
ble that practices such as douching, which is reportedly more
common in black women (46) and can increase susceptibility
to other STIs (47), could predispose to trichomoniasis and
explain the observed racial association. Increased preva-
lences of  Trichomonas infection could also reflect lack of
access to care and distrust of the health-care system, which
could manifest as failure to seek care, noncompliance with
treatment recommendations, and hesitation to refer part-
ners for treatment. Drug use and its association with high-
risk sexual behaviors, including trading sex for money or
drugs, may also explain the racial differences in the occur-
rence of  Trichomonas. In addition, compared with other
racial and ethnic groups, a greater proportion of blacks are
unmarried, divorced, or separated (48), and unmarried sta-
tus is itself a risk marker for STIs (49). It is also conceivable
that a genetic or racial-based heightened susceptibility to
T.vaginalis exists in African-Americans; however, such a
Table 2. Prevalence of  Trichomonas vaginalis among women, by
race, United States
City (ref)
Overall 
Tricho-
monas 
preva-
lence (%)
Tricho-
monas 
prevalence 
in blacks
Tricho-
monas 
prevalence 
in non-
blacks ORa
New York    
(18)
47 51 35 1.6
San 
Francisco 
(29)
11 28 9 3.7
5 cities (27) 13 23 6 4.4
Philadelphia 
(35)
16 30 11 3.6
New York 
(22)
27 population 
92% black
New York 
(25)
20 population 
83% black
Baltimore 
(24)
26 population 
96% black
New York 
(23)
20 population 
90% black
Baltimore 
(26)
25 population 
100% black
Birmingham 
(28)
21 population 
89% black
Providence 
(32)
3 population 
87% black
a Estimated odds ratio.Synopsis
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phenomenon has not been recognized. Finally, the observed
racial disparity could reflect strain differences of Trichomo-
nas. For example, if the strains that infect African-Ameri-
cans are more likely to produce chronic, persistent infection
of longer duration, higher prevalences would be observed.
However, this hypothesis has not been studied.
Trichomonas Compared with Other STIs in 
African-American Women
Table 3 lists studies comparing the prevalence of T. vag-
inalis infection with that of other STIs among black women
in the United States. In each study  Trichomonas was the
most commonly identified STI, exceeding both  Chlamydia
trachomatis and Neisseria gonorrhoeae in prevalence. While
the optimal tests for detecting C. trachomatis and N. gonor-
rhoeae were not always used in these studies, neither were
highly sensitive tests used for the diagnosis of Trichomonas. 
Discussion and Implications
The HIV/AIDS epidemic is a heterogeneous one, impact-
ing communities and subpopulations in disproportionate
ways. In many jurisdictions in the United States, HIV is
increasingly affecting low-income groups, particularly Afri-
can-Americans and women. We suggest that part of this phe-
nomenon may result from the amplifying effect of
T.vaginalis. Several aspects of the biology and epidemiology
of Trichomonas  suggest that this long-neglected protozoan
may play an important role in HIV transmission dynamics.
A compelling biologic rationale suggests that the pathology
caused by Trichomonas enhances the efficiency of HIV trans-
mission. In addition,  T. vaginalis infection is often asymp-
tomatic, and affected persons are likely to continue to engage
in sexual activity. This strong biologic plausibility is sup-
ported by empiric studies from Africa documenting that Tri-
chomonas may increase HIV transmission by two- to
threefold. Moreover, although imperfect, the available data
suggest that T. vaginalis is a highly prevalent infection, par-
ticularly among African-American women in urban commu-
nities of the United States. Given the evidence that
T.vaginalis likely promotes HIV infection, the apparent
high level of Trichomonas infection in black women is cause
for concern. Even if T. vaginalis  increases the risk of HIV
transmission by a small or modest amount, it may translate
into a sizable population effect since Trichomonas is so com-
mon. To illustrate this, we present population-attributable
risk curves, or the level of HIV transmission that would be
attributable to  T. vaginalis, at varying prevalences of Tri-
chomonas, given the assumption of an increased relative risk
of HIV infection of 2 or 3 (Figure). As the figure illustrates, if
Trichomonas amplifies HIV transmission by twofold and the
prevalence of T. vaginalis in a community is 25%, one fifth
(20%) of HIV transmission in that population would be
attributable to  Trichomonas. This has important implica-
tions for HIV prevention. Reduction in the prevalence of Tri-
chomonas could translate into substantial decreases in HIV
transmission. Effective, inexpensive single-dose therapy (2 g
oral metronidazole) is available for the treatment of T. vagi-
nalis infection. It may not be hyperbole to suggest that Tri-
chomonas infection may be more readily modifiable than
sexual behavior in some high-risk groups. Trials in Tanzania
have demonstrated the benefit of reduced HIV incidence in
communities receiving aggressive STD control intervention
(50).
While convincing data suggest that other STDs, includ-
ing both ulcerative and inflammatory infections, promote
HIV transmission (51), available evidence suggests that
T.vaginalis is the most common STI in African-American
women and therefore may play a more prominent role than
other STIs in augmenting the spread of HIV in this high-risk
group.
Additional studies to evaluate the prevalence and inci-
dence of T. vaginalis and to determine risk factors for infec-
tion in both men and women are needed. Moreover, given the
paucity of data and the potential importance of Trichomo-
nas, consideration should be given to requiring mandatory
reporting of T. vaginalis infection. Efforts to further evaluate
Table 3. Studies comparing the prevalence of Trichomonas vaginalis
infection with that of other sexually transmitted infections among
black women in the United States
Year City (ref)
Trichomonas 
(%)
Chlamydia
(%)
Gonorrhea 
(%)
1996 New York 
(18)
51 9 5
1994 New York 
(22)
27 7 2
1994 New York 
(23)
20 15 no data
1992 Baltimore 
(24)
26 21 14
1990
-94
New York 
(37)
22 6 1
1985 San 
Francisco 
(29)
28 25 no data
Figure. Hypothetical level of HIV transmission attributable to Tri-
chomonas vaginalis at varying prevalences of Trichomonas infection
and assuming that T. vaginalis infection amplifies HIV infection by
two- or three-fold. Synopsis
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the interactions between T. vaginalis and HIV, particularly
in an industrialized country setting, would also seem war-
ranted. However, given the lower rates of heterosexual
transmission, such studies would be expensive and require a
large sample. Nevertheless, we believe that current informa-
tion is compelling enough to warrant considering implemen-
tation of efforts to identify and treat persons with  T.
vaginalis infection, particularly African-Americans, in areas
of overlapping HIV and  T. vaginalis epidemics. Screening
programs using self-collected vaginal swabs (52) for culture
may be a reasonable method for such an effort. An alterna-
tive approach would be to first use wet mount examination,
which is relatively easy and inexpensive but lacks sensitiv-
ity, followed by culture for specimens that are negative on
wet mount. Recent development of sensitive and specific
urine-based diagnostic techniques can enhance both the
yield and ease of screening efforts (53); however, issues of
cost and accessibility may limit the use of such methods for
the average physician.
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